SOBIN-PD
Parkinson's Disease
PreclinicalActive
Key Facts
About AltPep
AltPep is pioneering a novel approach to amyloid diseases by targeting the toxic soluble oligomers that form early in disease progression, rather than the later-stage plaques. Founded in 2018 on decades of academic research from the University of Washington, the company has built a dual-purpose platform for both diagnostics (SOBA) and therapeutics (SOBIN). Its lead programs are in preclinical development for Alzheimer's and Parkinson's diseases, aiming to enable pre-symptomatic intervention in a market affecting over a billion people globally. The company is led by its founder and CEO, Dr. Valerie Daggett, who discovered the foundational α-sheet structure.
View full company profileTherapeutic Areas
Other Parkinson's Disease Drugs
| Drug | Company | Phase |
|---|---|---|
| NPT200-11 | Neuropore Therapies | Phase 1 |
| NUZ-001 | Neurizon Therapeutics | Preclinical |
| VXX-301 | Vaxxinity | Preclinical |
| BAN2802 | BioArctic | Phase 1 |
| CNM-Au8 | Clene | Phase 2 |
| hpSC-Derived Neural/Dopaminergic Cells | International Stem Cell | Preclinical/Early Clinical |
| SLS-004 | Seelos Therapeutics | Preclinical |
| SLS-007 | Seelos Therapeutics | Preclinical |
| Parkinson's Disease Portfolio (Platform-derived) | WD Pharmaceutical | Not Disclosed (Likely Preclinical/Early Clinical) |
| UX-DA001 | UniXell | Phase 1 |
| Parkinson's Disease Research | ProgenaBiome | Research |
| A9 Dopaminergic Neuron Therapy | Trailhead Biosystems | Pre-clinical |